Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report) passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $6.70 and traded as high as $9.00. Hemispherx BioPharma shares last traded at $6.70, with a volume of 7,639 shares.
Hemispherx BioPharma Stock Performance
The firm has a fifty day moving average price of $6.70 and a 200 day moving average price of $6.70.
About Hemispherx BioPharma
Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) is a U.S.-based biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of viral infections, cancers and immune system disorders. The company’s research centers on harnessing the body’s innate immune response to address diseases that currently lack broadly effective treatments.
Hemispherx’s principal commercial product is Alferon N Injection, an antiviral drug indicated for the treatment of external genital warts.
Featured Articles
- Five stocks we like better than Hemispherx BioPharma
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Put $1,000 into this stock by Jan 1 [Not NVDA]
- The $100 Trillion AI Story No One Is Telling You
- Buy this stock tomorrow?
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
